Table 1. Participant characteristics.
| Characteristic | ABC (n=461) | TDF (n=72) | AZT (n=30) | P-value, ABC versus THF | P-value, ABC versus AZT | P-value, TDF versus AZT |
|---|---|---|---|---|---|---|
| Male, % | 89 | 89 | 73 | 0.967 | 0.078 | 0.046 |
| Mean age, years (3D) | 46 (9.7) | 44 (9.6) | 50 (10.9) | 0.310 | 0.030 | 0.009 |
| African American, % | 39 | 39 | 40 | 0.989 | 0.964 | 0.934 |
| White, % | 57 | 58 | 53 | 0.871 | 0.811 | 0.668 |
| Mean CD4+T-cell count, cells/mm3 (3D) | 656 (232.4) | 585 (238.8) | 725 (370.3) | 0.167 | 0.274 | 0.018 |
| Mean NRTI therapy duration, days (3D) | 1,462 (277.7) | 1,303 (424.1) | 3,761 (1,499.3) | 0.015 | <0.001 | <0.001 |
| Current smoker, % | 22 | 33 | 30 | 0.210 | 0.490 | 0.834 |
| Current statin treatment, % | 8.7 | 11.1 | 30.0 | 0.740 | 0.029 | 0.022 |
| Companion ART | ||||||
| NNRT1, % | 33 | 43 | 67 | 0.294 | 0.054 | 0.219 |
| PI, % | 67 | 48 | 27 | 0.041 | <0.001 | 0.059 |
| Other, % | 0 | 9 | 17 | 0.031 | 0.005 | 0.355 |
ABC, abacavir; ART, antiretroviral therapy; AZT, zidovudine; NNRTI, non-nucleoskJe reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir.